English

Cessatech A/S publishes annual report for the fiscal year 2021

Report this content

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2021. The annual report including the auditor’s report is attached as a pdf. The report is also available on Cessatech’s website www.cessatech.com under ‘Fillings & Reports’

Full year 2021 (1 January – 31 December):

  • Net revenue was KDKK 0 
  • Operating result was KDKK -13,833 
  • Net result was KDKK -11,569
  • Cash at bank end of the period was KDKK 3.275 
  • Earnings per share* was KDKK -3.09
  • Solidity** was 86%

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 December 2021 amounted to 6.112.535 shares, the average number of shares during the full year was 3,740,145

 There has been an increase in the number of shares in Q4 related to the exercise of warrant TO 1.

 **Solidity: Total equity divided by total capital and liability.

Highlights during the full year 2021

Q1-2021

  • Published favourable data from the Registry Safety Study (0203)
  • Awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial 
  • Reported first subject dosed in bioavailability trial 0204 of lead product candidate
  • Clinical submissions finalised for trial 0206 
  • Building the organisational team to lead the final development of CT001

Q2-2021

  • Completed recruitment for trial 0204
  • Ready to initiate recruitment for trial 0206
  • Initiated formulation activities of CT002
  • Awarded IPO of the year by Affärsvälden 
  • Appointed Adam Steensberg as Chairman of the Board

Q3-2021

  • Initiated (first patient enrolled) and ongoing recruitment for trial 0206
  • Submitted protocol for authorities approval for trial 0205
  • Finalisation of GMP clinical manufacturing batch production of CT001 for trial 0205
  • Continue to build the organisation to execute the final development of CT001

Q4-2021

  • Improved recruitment for trial 0206 
  • Final statistical analysis of trial 0204 ongoing, final results should be ready any day
  • Successful warrant TO 1 exercise, overall exercise rate of approximately 97 percent
  • Announced the issuance of the company’s first US patent covering CT001
  • Preparation of US regulatory strategy 

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is at its pivotal stage of clinical development.

Subscribe

Documents & Links